This is an observational, ambrispective study of patients in real world clinical practice, who has pulmonary arterial hypertension in whom a prostacyclin IP receptor agonist (Selexipag) is initiated between 2017 and 2021.

The aim of this study answer the following questions:

• Changes in the mortality risk profile of these patients after treatment administration.
• Baseline characteristics of patients initiating Selexipag.
• Parameters used for risk stratification prior to treatment escalation.
• Events during follow-up.

No comparison group available

Inclusion Criteria:

• They agree to participate in the study by signing an informed consent form

Exclusion Criteria:

• Decline to participate in the study
• Patients living 6 months or less in the reference health area
• Patients with active malignant tumors

Patients with pulmonary arterial hypertension (mostly intermediate risk patients) who are started on treatment with Selexipag according to clinical practice guideline recommendations.

Once the database has been completed and the main results article has been published, access to the database through a free repository (e.g. Mendeley) will be considered.